🇺🇸 CRS-207 in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malignant Neoplasm Progression — 4 reports (16.67%)
  2. Dehydration — 3 reports (12.5%)
  3. Pneumonia — 3 reports (12.5%)
  4. Sepsis — 3 reports (12.5%)
  5. Acute Kidney Injury — 2 reports (8.33%)
  6. Cholangitis — 2 reports (8.33%)
  7. Diarrhoea — 2 reports (8.33%)
  8. Rectal Haemorrhage — 2 reports (8.33%)
  9. Syncope — 2 reports (8.33%)
  10. Abdominal Pain — 1 report (4.17%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is CRS-207 approved in United States?

CRS-207 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CRS-207 in United States?

Aduro Biotech, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.